ASS1 overexpression effectively inhibited tumor growth and strengthened the efficacy of combination chemotherapy via activation of the PERK/eIF2α/ATF4/CHOP axis, which is independent of the status of p53 and arginine metabolism (39). Here, EIF2A is linked to neoplasm.